Tags

Type your tag names separated by a space and hit enter

Current advances in the development of SARS-CoV-2 vaccines.
Int J Biol Sci. 2021; 17(1):8-19.IJ

Abstract

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a global pandemic that has wreaked havoc globally, which has put a heavy toll on public health, lives, and the world economy. Vaccination is considered as one of the greatest successes in medical history. Based on prior experience with the development of SARS-CoV vaccines, all COVID-19 vaccines must be subjected to the tests for protective effects and harmful risks derived from antibody-dependent enhancement that may contribute to augmented infectivity and/or eosinophilic infiltration. The SARS-CoV-2 vaccine is now being developed urgently in several different ways. China is regarded as one of the world's leading countries in SARS-CoV-2 vaccine development, up to date the last inactivated vaccine international clinical (Phase III) trial was launched in the United Arab Emirates by Sinopharm China National Biotec Group (CNBG). In this review, we outline the current status of vaccine development against clinically relevant SARS-CoV-2 strains, anticipating that such attempts would help create efficacious and sage SARS-CoV-2 vaccines.

Authors+Show Affiliations

Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, China. Department of Biochemistry & Food Sciences, University of Kordofan, El-Obeid, 51111, Sudan.Lab of Molecular Immunology, Virus Inspection Department, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, 310051, China.Center for Medical Innovation, Nagasaki University, 1-7-1 Sakamoto, Nagasaki 852-8588, Japan.Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, China.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

33390829

Citation

Awadasseid, Annoor, et al. "Current Advances in the Development of SARS-CoV-2 Vaccines." International Journal of Biological Sciences, vol. 17, no. 1, 2021, pp. 8-19.
Awadasseid A, Wu Y, Tanaka Y, et al. Current advances in the development of SARS-CoV-2 vaccines. Int J Biol Sci. 2021;17(1):8-19.
Awadasseid, A., Wu, Y., Tanaka, Y., & Zhang, W. (2021). Current advances in the development of SARS-CoV-2 vaccines. International Journal of Biological Sciences, 17(1), 8-19. https://doi.org/10.7150/ijbs.52569
Awadasseid A, et al. Current Advances in the Development of SARS-CoV-2 Vaccines. Int J Biol Sci. 2021;17(1):8-19. PubMed PMID: 33390829.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current advances in the development of SARS-CoV-2 vaccines. AU - Awadasseid,Annoor, AU - Wu,Yanling, AU - Tanaka,Yoshimasa, AU - Zhang,Wen, Y1 - 2021/01/01/ PY - 2020/08/29/received PY - 2020/10/22/accepted PY - 2021/1/4/entrez PY - 2021/1/5/pubmed PY - 2021/1/15/medline KW - COVID-19 KW - SARS-CoV-2 KW - clinical trial KW - coronavirus KW - vaccines SP - 8 EP - 19 JF - International journal of biological sciences JO - Int J Biol Sci VL - 17 IS - 1 N2 - Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a global pandemic that has wreaked havoc globally, which has put a heavy toll on public health, lives, and the world economy. Vaccination is considered as one of the greatest successes in medical history. Based on prior experience with the development of SARS-CoV vaccines, all COVID-19 vaccines must be subjected to the tests for protective effects and harmful risks derived from antibody-dependent enhancement that may contribute to augmented infectivity and/or eosinophilic infiltration. The SARS-CoV-2 vaccine is now being developed urgently in several different ways. China is regarded as one of the world's leading countries in SARS-CoV-2 vaccine development, up to date the last inactivated vaccine international clinical (Phase III) trial was launched in the United Arab Emirates by Sinopharm China National Biotec Group (CNBG). In this review, we outline the current status of vaccine development against clinically relevant SARS-CoV-2 strains, anticipating that such attempts would help create efficacious and sage SARS-CoV-2 vaccines. SN - 1449-2288 UR - https://www.unboundmedicine.com/medline/citation/33390829/Current_advances_in_the_development_of_SARS_CoV_2_vaccines_ L2 - https://www.ijbs.com/v17p0008.htm DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.